T1 mapping and survival in systemic light-chain amyloidosis

Aims To assess the prognostic value of myocardial pre-contrast T1 and extracellular volume (ECV) in systemic amyloid light-chain (AL) amyloidosis using cardiovascular magnetic resonance (CMR) T1 mapping. Methods and results One hundred patients underwent CMR and T1 mapping pre- and post-contrast. Myocardial ECV was calculated at contrast equilibrium (ECVi) and 15 min post-bolus (ECVb). Fifty-four healthy volunteers served as controls. Patients were followed up for a median duration of 23 months and survival analyses were performed. Mean ECVi was raised in amyloid (0.44 ± 0.12) as was ECVb (mean 0.44 ± 0.12) compared with healthy volunteers (0.25 ± 0.02), P < 0.001. Native pre-contrast T1 was raised in amyloid (mean 1080 ± 87 ms vs. 954 ± 34 ms, P < 0.001). All three correlated with pre-test probability of cardiac involvement, cardiac biomarkers, and systolic and diastolic dysfunction. During follow-up, 25 deaths occurred. An ECVi of >0.45 carried a hazard ratio (HR) for death of 3.84 [95% confidence interval (CI): 1.53–9.61], P = 0.004 and pre-contrast T1 of >1044 ms = HR 5.39 (95% CI: 1.24–23.4), P = 0.02. Extracellular volume after primed infusion and ECVb performed similarly. Isolated post-contrast T1 was non-predictive. In Cox regression models, ECVi was independently predictive of mortality (HR = 4.41, 95% CI: 1.35–14.4) after adjusting for E:E′, ejection fraction, diastolic dysfunction grade, and NT-proBNP. Conclusion Myocardial ECV (bolus or infusion technique) and pre-contrast T1 are biomarkers for cardiac AL amyloid and they predict mortality in systemic amyloidosis.

[1]  L. Kuller,et al.  Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. , 2014, European heart journal.

[2]  C. Kramer,et al.  Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping , 2013, Journal of magnetic resonance imaging : JMRI.

[3]  G. Merlini,et al.  Prognostic value of fragmented QRS in cardiac AL amyloidosis. , 2013, International journal of cardiology.

[4]  S. Punwani,et al.  Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. , 2013, Radiology.

[5]  M. Robson,et al.  T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. , 2013, JACC. Cardiovascular imaging.

[6]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[7]  A. Flett,et al.  Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis: An Equilibrium Contrast Cardiovascular Magnetic Resonance Study , 2013, Circulation. Cardiovascular imaging.

[8]  F. Miller,et al.  Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study: reply. , 2013, European heart journal cardiovascular Imaging.

[9]  M. Koestenberger.  Early impairment of systolic right ventricular function parameters in patients with primary systemic amyloidosis. , 2013, European heart journal cardiovascular Imaging.

[10]  Andrew S Flett,et al.  Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR , 2012, Journal of Cardiovascular Magnetic Resonance.

[11]  R. Falk,et al.  Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. , 2012, JACC. Cardiovascular imaging.

[12]  Andrew S Flett,et al.  Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease , 2012, Heart.

[13]  P. Pellikka,et al.  Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. , 2012, European heart journal cardiovascular Imaging.

[14]  P. Kellman,et al.  Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. , 2012, European heart journal.

[15]  H. Niessen,et al.  T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. , 2012, Circulation. Cardiovascular imaging.

[16]  J. Moon,et al.  Updates in Cardiac Amyloidosis: A Review , 2012, Journal of the American Heart Association.

[17]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[19]  M. Hayward,et al.  Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.

[20]  T. Abraham,et al.  Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[21]  R. Falk,et al.  Prognostic significance of strain Doppler imaging in light-chain amyloidosis. , 2010, JACC. Cardiovascular imaging.

[22]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[23]  D. Pennell,et al.  Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[24]  Charles E McCulloch,et al.  Relaxing the rule of ten events per variable in logistic and Cox regression. , 2007, American journal of epidemiology.

[25]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[27]  R. Falk,et al.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.

[28]  J. Carroll,et al.  Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. , 1982, The American journal of cardiology.